Patient-reported outcomes of a multicenter phase 2 study investigating gemcitabine and stereotactic body radiation therapy in locally advanced pancreatic cancer Academic Article uri icon

Overview

MeSH Major

  • Antimetabolites, Antineoplastic
  • Deoxycytidine
  • Pancreatic Neoplasms
  • Patient Reported Outcome Measures
  • Quality of Life
  • Radiosurgery

abstract

  • Global QoL scores are not reduced with gemcitabine and SBRT. In this exploratory analysis, patients experience clinically relevant short-term improvements in pancreatic cancer-specific symptoms. Previously demonstrated acceptable clinical outcomes combined with these favorable QoL data indicate that SBRT can be easily integrated with other systemic therapies and may be a potential standard of care option in patients with LAPC.

publication date

  • November 2016

Research

keywords

  • Academic Article

Identity

Language

  • eng

PubMed Central ID

  • PMC5572652

Digital Object Identifier (DOI)

  • 10.1016/j.prro.2016.05.005

PubMed ID

  • 27552809

Additional Document Info

start page

  • 417

end page

  • 424

volume

  • 6

number

  • 6